Latest Breaking News On - கிரெகொரி ஃபியரி - Page 1 : comparemela.com
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a biallelic knockout of a key MHC class I gene. Exacis cell engineering strategy is designed to allow its ExaNK™ cells to evade surveillance by the patient s immune system, thus rendering the cells rejection resistant, or stealth , to enable increased persistence in patients without genotoxic pre-conditioning.
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis next generation approach avoids use of DNA and viruses by using mRNA. The technologies will be used for generating iPSC and for performing genetic editing to create stealthed, allogeneic cell products, termed ExaCAR-T™ or ExaCAR-NK™ cells.